Tetrahydrofuran

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Chemical-gene interaction
• Descriptors
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:1601226	IVR	5000 mg/L	5000 mg/L	Affects skeletal development	Developmental endocrine-mediated perturbations
	IVR	5000 mg/L	5000 mg/L	Affects embryonic development	Developmental endocrine-mediated perturbations
	IVR	5000 mg/L	5000 mg/L	Affects survival of live fetus	Reproductive endocrine-mediated perturbations
	IVR	5000 mg/L	5000 mg/L	Decreased uterine weights	Reproductive endocrine-mediated perturbations
	IVR	1800 mg/L	1800 mg/L	Affects survival of live fetus	Reproductive endocrine-mediated perturbations
	IVR	1800 mg/L	1800 mg/L	Affects skeletal development	Developmental endocrine-mediated perturbations
	IVR	1800 mg/L	1800 mg/L	Affects embryonic development	Developmental endocrine-mediated perturbations
	IVR	1800 mg/L	1800 mg/L	Decreased uterine weights	Reproductive endocrine-mediated perturbations
	IVR	600 mg/L	-	No significant effects observed	-
PMID:2318358	IVR	5000 mg/L	5000 mg/L	Decreased thymus gland weights	Immunological endocrine-mediated perturbations
	IVR	5000 mg/L	5000 mg/L	Changes in adrenal gland morphology	Metabolic endocrine-mediated perturbations
	IVR	5000 mg/L	5000 mg/L	Decreased spleen weights	Immunological endocrine-mediated perturbations
	IVR	5000 mg/L	5000 mg/L	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	5000 mg/L	5000 mg/L	Uterine atrophy	Reproductive endocrine-mediated perturbations
	IVR	5000 mg/L	5000 mg/L	Gait abnormality	Developmental endocrine-mediated perturbations
	IVR	1800 mg/L	1800 mg/L	Decreased thymus gland weights	Immunological endocrine-mediated perturbations
	IVR	1800 mg/L	1800 mg/L	Gait abnormality	Developmental endocrine-mediated perturbations
	IVR	1800 mg/L	1800 mg/L	Decreased spleen weights	Immunological endocrine-mediated perturbations
	IVR	1800 mg/L	1800 mg/L	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	600 mg/L	600 mg/L	Increased liver weights	Hepatic endocrine-mediated perturbations
	IVR	600 mg/L	600 mg/L	Decreased thymus gland weights	Immunological endocrine-mediated perturbations
	IVR	600 mg/L	600 mg/L	Decreased spleen weights	Immunological endocrine-mediated perturbations
	IVR	200 mg/L	-	No significant effects observed	-
	IVR	66 mg/L	-	No significant effects observed	-

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.